⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65108 | 0.71 | — | — | |
| SCHEMBL67956 | 0.71 | — | — | |
| SCHEMBL25317373 | 0.70 | — | — | |
| Iodide SCHEMBL27655122 | 0.69 | — | — | |
| SCHEMBL27150056 | 0.69 | — | — | |
| Methane SCHEMBL27872321 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL7285171 | 0.69 | — | — | |
| SCHEMBL7927719 | 0.69 | — | — | |
| SCHEMBL14383210 | 0.67 | HPGD (0.31) | — | |
| SCHEMBL5216842 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109643752-A | FLEXIBLE PIEZOELECTRIC AND FERROELECTRIC HALOIMIDAZOLE CRYSTALS | 西北大学 | 2019-04-16 | — | — | CN | claimed |
| CN-122036605-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| WO-2025217147-A1 | METAL-ORGANIC FRAMEWORK NANOPARTICLES AND METHODS OF MAKING THE SAME | CARNEGIE MELLON UNIVERSITY (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | UNIVERSITE DE MONTREAL (CA) | 2025-08-28 | — | — | US | disclosed |
| EP-4584249-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580621-A2 | T-TYPE VOLTAGE-GATED CALCIUM CHANNEL POTENTIATORS | The Broad Institute, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| CN-120091815-A | T-type voltage-gated calcium channel enhancer | 广泛研究所股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| EP-1786839-A1 | WATER-SOLUBLE CELLULOSE DERIVATIVE COMPRISING A LIGAND | Akzo Nobel N.V. (NL) | 2007-05-23 | — | — | EP | disclosed |
| US-6984646-B2 | Imidazopyridinones as p38 map kinase inhibitors | BAYER HEALHCARE AG (DE) | 2006-01-10 | — | — | US | disclosed |
| WO-2006000582-A1 | WATER-SOLUBLE CELLULOSE DERIVATIVE COMPRISING A LIGAND | AKZO NOBEL N.V. (NL) | 2006-01-05 | — | — | WO | disclosed |
| EP-1412353-B1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-03-02 | — | — | EP | disclosed |
| US-20040220208-A1 | Imidazopyridinones as p38 map kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2004-11-04 | — | — | US | disclosed |
| EP-1412353-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003008413-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
| CN-1335847-A | Sulfonamide compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-02-13 | — | — | CN | disclosed |
| CN-1268942-A | Sulfonamide compounds and medicinal use thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-10-04 | — | — | CN | disclosed |